Norgine Ventures

Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. Norgine Ventures is backed by Norgine, a fully integrated, private, European healthcare company with over 110 years of experience in the pharma space. Norgine Ventures has full access to Norgine’s technical capabilities for evaluating investment opportunities, although the business is aimed at achieving a financial return rather than funding opportunities of strategic interest to Norgine. To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.

Focus

Series B Mid Venture Dental Virtual Reality Simulation Show more

http://www.norgineventures.com

http://www.norgineventures.com/

https://crunchbase.com/organization/norgine-ventures

Yakhya Azashikov

Associate Director

Iakhia Azashikov

Associate Director

Jackie Burton

Finance Director

Grethe Dalsgaard

Associate Director, Scientific Evaluation

Julien Michaux

MD

Lira Popovska

Investment Professional

Moritz Reuter

Investment Associate

Peter Stein

Chairman and CEO

20 past transactions

Magentiq Eye Ltd

Convertible Note in 2021

Magentiq Eye Ltd., a medical device company, which provides products for endoscopic medical procedures. The company offers automatic polyp detection system (APDS); APDS- RT, a software that runs on local device and server and gets the video feed from the endoscopic camera used by the physician in real time; and APDS-OFL, a software that runs in offline mode on pre-recorded colonoscopy videos. It also provides big data management and analysis, computer vision, video analysis, and colonoscopy screening test. The company was founded in 2014 and is based in Haifa, Israel.

Caresyntax

Venture Round in 2017

At caresyntax, your core mission is to bridge the variability gap of processes and outcomes in surgery and interventional radiology. We raise the surgical performance bar by empowering clinicians with actionable, enterprise-level data analytics.

Impress

Series B in 2022

Impress is the only truly orthodontic DTC player… globally We have a defensible model with the personal touch of an in-house orthodontist, true clinical expertise, and engaging directly with consumers

PulseCath

Venture Round in 2016

PulseCath is a medical device company, develops, manufactures, and markets circulatory support systems to cardiologists and cardiac surgeons in the Netherlands and internationally. It offers iVAC 3L, a mid-range minimal heart circulatory assist device that generates up to three liters per minute, and offers critical hemodynamic support in the case of left ventricular failure or during high-risk revascularization procedures with potential post cardiotomy weaning complications.

Medical Vision

Debt Financing in 2012

Medical Vision AB develops, constructs, and produces medical devices used during endoscopic procedures. It offers arthro-tube products, arthroscopy pumps, arthroscopy sets, receptacles, digital camera systems, capture devices, fluid management systems, and double pumps.

SpineGuard

Venture Round in 2012

The primary objective of SpineGuard is to establish PediGuardÂ® as the STANDARD OF CARE FOR SAFER PEDICLE SCREW PLACEMENT to the benefit of patients, surgeons and health care providers as well as the shareholders, employees and partners of SpineGuard. Secondarily, SpineGuard is exploring other applications for the PediGuard technology platform provided that they are in line with the SpineGuard mission.

PathoQuest

Series A in 2019

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Agendia

Debt Financing in 2014

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Stanmore Implants Worldwide

Debt Financing in 2013

Stanmore Implants Worldwide is an innovative orthopaedic business focused on the design and manufacture of both bespoke and modular implants for limb-sparing and complex primary and revision joint replacement. Stanmore Implants Worldwide designs, manufactures and markets a custom implant service alongside a portfolio of orthopaedic implants for limb salvage and complex joint replacement, and is known for creating some of the world's most successful implants. Stanmore Implants Worldwide acquired its robotic bone preparation technology through the acquisition of Acrobot, a medical devices company specializing in computer-assisted orthopaedic surgery in August 2010. Stanmore Implants Worldwide was acquired by Stryker on April 29, 2016. It was founded in 1948 and is headquartered in London, UK.

SpineVision

Venture Round in 2014

SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed in collaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents. SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States.

ImaginAb

Venture Round in 2021

ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.

Collagen Solutions

Post in 2017

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics. Our capabilities include the provision of native, soluble and powdered collagen formulations and expertise in the development and contract manufacture of collagen components for use as tissue scaffolds and medical devices. Collagen Solutions' unique offering extends beyond material supply and contract services as our highly skilled staff support customers through various stages of development and regulatory approval, establishing long-term commercial relationships.

EBS Technologies

Venture Round in 2017

EBS Technologies GmbH develops and commercializes stimulation devices for the treatment of neurologically caused impairments such as visual field loss. Additionally, the company offers EBS Therapy, a non-invasive optic nerve stimulation therapy deploying electrical currents, resulting in neuroregeneration and neuroprotection. EBS Technologies GmbH was founded in 2007 and is headquartered in Hennigsdorf, Germany.

Inovus Ltd

Venture Round in 2022

Inovus Ltd designs and manufactures medical simulation products. The company’s products include take-home laparoscopic simulators and institutional based laparoscopic simulators, as well as simulators for teaching skills in critical care, medicine, and surgery. It serves customers online. The company was founded in 2012 and is based in Saint Helens, United Kingdom.

Internis Pharmaceuticals

Debt Financing in 2013

Internis is an exciting and innovative British start-up business. Founded in 2010, it is a pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency. Internis supplies a prescription only licensed medicine (FultiumD3) to treat patients with a vitamin D deficiency. Vitamin D is offered to at-risk groups on prescription to prevent the health risks associated with a deficiency or insufficiency. It is estimated that up to a quarter of the population in the UK have low levels of vitamin D in their blood – with deficiency linked to conditions including bone deformities and health complications such as depression, joint pain, migraines, fatigue and a weakened immune system.

Q3 Medical Devices

Venture Round in 2016

Q3 Medical Devices Limited is a holding company, which through its subsidiaries, engages in the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with coronary, peripheral vascular, and nonvascular diseases. The company was founded in 2013 and is based in Dublin, Ireland.

SpineGuard

Post in 2018

Azanta

Venture Round in 2014

Azanta A/S, a biopharmaceutical company, develops and sells treatments for orphan oncology and women’s health indications. It also offers obstetrics and addiction medicines. The company was formerly known as IPC International A/S and changed its name to Azanta A/S in February 2010. Azanta A/S was founded in 1994 and is based in Copenhagen, Denmark. As of March 24, 2020, Azanta A/S operates as a subsidiary of Norgine B.V.

Magentiq Eye Ltd

Series A in 2019

SuperSonic Imagine

Venture Round in 2014

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.